Approval · Notice of Compliance 33952 · 2016
IPG-GABAPENTIN: Notice of Compliance 33952
Issued November 17, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33952
- Date
- November 17, 2016
- Company
- Marcan Pharmaceuticals Inc.Ottawa, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Bristol-Myers Squibb/Sanofi-Synthelabo Canada Inc.,
- Canadian reference product
- NEURONITIN (Pfizer Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IPG-GABAPENTIN | 02390949 | Approved |
| IPG-GABAPENTIN | 02390957 | Approved |
| IPG-GABAPENTIN | 02390965 | Approved |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP